Ketoconazole and itraconazole may have serum concentrations increased due to CYP3A inhibition by Kaletra. High doses of ketoconazole and itraconazole (greater than 200 mg/day) are not recommended.
Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.

Coadministration of ketoconazole (200 mg single dose) and lopinavir/ritonavir (400/100 mg twice daily for 16 days) to 12 HIV- subjects resulted in decreases in lopinavir Cmax, AUC and Cmin of 11%, 13% and 25% respectively. Ketoconazole Cmax increased by 13% and there was a 3-fold increase in AUC. High doses of ketoconazole (greater than 200 mg/day) are not recommended.
Kaletra Prescribing Information, AbbVie Ltd, October 2020.

Increases in lopinavir and ritonavir Cmin of 68% and 33% respectively were reported in an HIV+ patient receiving Kaletra (400/100 mg twice daily) following the addition of ketoconazole (200 mg once daily). Despite the increase in lopinavir and ritonavir concentrations (and the suspected increase in ketoconazole concentrations), no relevant side effects were observed.
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. Boffito M, Bonora S, Sales S, et al. AIDS Res Hum Retroviruses, 2004, 19: 941-942.